Global Cancer Monoclonal Antibodies Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cancer Monoclonal Antibodies Market Research Report 2024
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
According to Mr Accuracy reports’s new survey, global Cancer Monoclonal Antibodies market is projected to reach US$ 63810 million in 2034, increasing from US$ 34310 million in 2022, with the CAGR of 9.2% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cancer Monoclonal Antibodies market research.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Monoclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Cancer Monoclonal Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Cancer Monoclonal Antibodies market is projected to reach US$ 63810 million in 2034, increasing from US$ 34310 million in 2022, with the CAGR of 9.2% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cancer Monoclonal Antibodies market research.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cancer Monoclonal Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Segment by Type
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Cancer Monoclonal Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices